IGC Pharma erweitert Alzheimer-Studie nach Kolumbien

Reuters

Feb 09

<a href="https://laohu8.com/S/IGC">IGC Pharma</a> erweitert Alzheimer-Studie nach Kolumbien

IGC Pharma Inc. erweitert seine Phase-2-Studie CALMA zur Alzheimer-Behandlung durch die Zusammenarbeit mit dem renommierten Forschungszentrum Grupo de Neurociencias de Antioquia (GNA) in Kolumbien. Mit dieser Expansion stärkt das Unternehmen die genetische Vielfalt seiner klinischen Studie und baut seine internationale Präsenz auf insgesamt 23 aktive Standorte in den USA, Kanada und nun auch Südamerika aus. Die Einbindung des GNA, das weltweit für seine Forschung zu erblich bedingtem Alzheimer bekannt ist, stellt einen wichtigen Meilenstein auf dem Weg zu den für 2026 erwarteten Studiendaten dar.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IGC Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1134574) on February 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610653754"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610653754\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610653754?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-09 21:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610653754","market":"nz","top_or_hot":-1,"title":"IGC Pharma erweitert Alzheimer-Studie nach Kolumbien","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/IGC\">IGC Pharma</a> erweitert Alzheimer-Studie nach Kolumbien\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IGC Pharma Inc. erweitert seine Phase-2-Studie CALMA zur Alzheimer-Behandlung durch die Zusammenarbeit mit dem renommierten Forschungszentrum Grupo de Neurociencias de Antioquia (GNA) in Kolumbien. Mit dieser Expansion stärkt das Unternehmen die genetische Vielfalt seiner klinischen Studie und baut seine internationale Präsenz auf insgesamt 23 aktive Standorte in den USA, Kanada und nun auch Südamerika aus. Die Einbindung des GNA, das weltweit für seine Forschung zu erblich bedingtem Alzheimer bekannt ist, stellt einen wichtigen Meilenstein auf dem Weg zu den für 2026 erwarteten Studiendaten dar.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IGC Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1134574) on February 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IGC Pharma erweitert Alzheimer-Studie nach Kolumbien</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIGC Pharma erweitert Alzheimer-Studie nach Kolumbien\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-09 21:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/IGC\">IGC Pharma</a> erweitert Alzheimer-Studie nach Kolumbien\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IGC Pharma Inc. erweitert seine Phase-2-Studie CALMA zur Alzheimer-Behandlung durch die Zusammenarbeit mit dem renommierten Forschungszentrum Grupo de Neurociencias de Antioquia (GNA) in Kolumbien. Mit dieser Expansion stärkt das Unternehmen die genetische Vielfalt seiner klinischen Studie und baut seine internationale Präsenz auf insgesamt 23 aktive Standorte in den USA, Kanada und nun auch Südamerika aus. Die Einbindung des GNA, das weltweit für seine Forschung zu erblich bedingtem Alzheimer bekannt ist, stellt einen wichtigen Meilenstein auf dem Weg zu den für 2026 erwarteten Studiendaten dar.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IGC Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1134574) on February 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IGC","symbol_name":"IGC Pharma","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDL5X9pf5:1","article_id":"2610653754","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610653754","pubTimestamp":1770643851,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"IGC Pharma Inc. erweitert seine Phase-2-Studie CALMA zur Alzheimer-Behandlung durch die Zusammenarbeit mit dem renommierten Forschungszentrum Grupo de Neurociencias de Antioquia  in Kolumbien. Mit dieser Expansion strkt das Unternehmen die genetische Vielfalt seiner klinischen Studie und baut seine internationale Prsenz auf insgesamt 23 aktive Standorte in den USA, Kanada und nun auch Südamerika aus. Die Einbindung des GNA, das weltweit für seine Forschung zu erblich bedingtem Alzheimer bekannt ist, stellt einen wichtigen Meilenstein auf dem Weg zu den für 2026 erwarteten Studiendaten dar.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IGC Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IGC":"IGC Pharma","BK4007":"制药","BK4104":"贸易公司与经销商"},"translate_title":"IGC Pharma将阿尔茨海默病研究扩展到哥伦比亚","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IGC":0.9},"content_text":"IGC Pharma erweitert Alzheimer-Studie nach Kolumbien\n    \n\n        IGC Pharma Inc. erweitert seine Phase-2-Studie CALMA zur Alzheimer-Behandlung durch die Zusammenarbeit mit dem renommierten Forschungszentrum Grupo de Neurociencias de Antioquia (GNA) in Kolumbien. Mit dieser Expansion stärkt das Unternehmen die genetische Vielfalt seiner klinischen Studie und baut seine internationale Präsenz auf insgesamt 23 aktive Standorte in den USA, Kanada und nun auch Südamerika aus. Die Einbindung des GNA, das weltweit für seine Forschung zu erblich bedingtem Alzheimer bekannt ist, stellt einen wichtigen Meilenstein auf dem Weg zu den für 2026 erwarteten Studiendaten dar.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IGC Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1134574) on February 09, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}